Skip to main content

Advertisement

SpringerLink
Log in

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr-Abl kinase, imatinib leads to durable cytogenetic remissions and in turn improved survival. However, many patients with CML develop resistance, fail to respond, or become intolerant to imatinib due to side effects. This has spurred interest in developing second-generation TKIs to overcome the mechanisms of resistance that lead to treatment failure, specifically Bcr-Abl1 kinase domain mutations. Two second-generation TKIs, nilotinib and dasatinib, are approved for the treatment of CML after imatinib failure or intolerance. Unfortunately, many patients fail subsequent treatment with these agents, as they can develop highly resistant mutations such as T315I. Various other strategies are now in use to optimize the treatment of CML, including dose optimization of imatinib, combination therapy, upfront use of second-generation TKIs, and use of maintenance therapy with interferon-α and vaccines. This review highlights progress made in the treatment of CML in the past year.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561–566.

    Article  CAS  PubMed  Google Scholar 

  2. O’Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003, 348:994–1004.

    Article  PubMed  Google Scholar 

  3. Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.

    Article  CAS  PubMed  Google Scholar 

  4. Deininger M, O’Brien SG, Guilhot F, et al.: International Randomized Study of Interferon versus STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 1126.

  5. de Lavallade H, Apperley JF, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358–3363.

    Article  PubMed  Google Scholar 

  6. Baccarani M, Saglio G, Goldman J, et al.: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809–1820.

    Article  CAS  PubMed  Google Scholar 

  7. Alvarado Y, Kantarjian H, O’Brien S, et al.: Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009, 115:3709–3718.

    Article  CAS  PubMed  Google Scholar 

  8. Apperley JF: Part I. Mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007, 8:1018–1029.

    Article  CAS  PubMed  Google Scholar 

  9. O’Hare T, Walters DK, Stoffregen EP, et al. : In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505.

    Article  PubMed  Google Scholar 

  10. Branford S: Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007, 376–383.

  11. Willis SG, Lange T, Demehri S, et al.: High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128–2137.

    Article  CAS  PubMed  Google Scholar 

  12. Shah NP, Skaggs BJ, Branford S, et al.: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562–2569.

    Article  CAS  PubMed  Google Scholar 

  13. Quintás-Cardama A, Gibbons DL, Kantarjian HM, et al.: Mutational analysis of chronic phase chronic myeloid leukemia (CML-CP) clones reveals heightened BCR-ABL1 genetic instability in patients failing sequential imatinib and dasatinib therapy [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 2114.

  14. Wang L, Giannoudis A, Lane S, et al.: Expression of the uptake drug transported hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83:258–264.

    Article  CAS  PubMed  Google Scholar 

  15. Goldman J, Gordon M: Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter? Leuk Lymphoma 2006, 47:1–7.

    Article  CAS  PubMed  Google Scholar 

  16. Bantscheff M, Eberhard D, Abraham Y, et al.: Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035–1044.

    Article  CAS  PubMed  Google Scholar 

  17. Baccarani M, Rosti G, Saglio G, et al.: Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 450.

  18. Mauro MJ, Baccarani M, Cervantes F, et al.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008, 26(Suppl):Abstract 7009.

  19. Apperley JF, Cortes JE, Kim DW, et al.: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009, 27:3472–3479.

    Article  CAS  PubMed  Google Scholar 

  20. Cortes J, Kim DW, Raffoux E, et al.: Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22:2176–2183.

    Article  CAS  PubMed  Google Scholar 

  21. Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009,113:2154–2160.

    Article  CAS  PubMed  Google Scholar 

  22. Kantarjian H, Pasquini R, Lévy V, et al.: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistance to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136–4147.

    Article  CAS  PubMed  Google Scholar 

  23. Stone RM, Kim DW, Kantarjian HM, et al.: Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival [abstract]. J Clin Oncol 2009, 27(Suppl):Abstract 7007.

  24. Quintás-Cardama A, Cortes J, O’Brien S, et al.: Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009, 115:2912–2921.

    Article  PubMed  Google Scholar 

  25. Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129–141.

    Article  CAS  PubMed  Google Scholar 

  26. Kantarjian H, Giles F, Bhalla K, et al.: Nilotinib in chronic myeloid leukemia patients in chronic phase with imatinib resistance or intolerance: longer follow-up of a phase II study [abstract]. J Clin Oncol 2009, 27(Suppl):Abstract 7029.

  27. Le Coutre PD, Giles F, Hochhaus A, et al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase with imatinib resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol 2009, 27(Suppl):Abstract 7057.

  28. Giles FJ, Larson RA, Kantarjian HM, et al.: Nilotinib in patients with Philadelphia chromosome positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. J Clin Oncol 2008, 26(Suppl):Abstract 7017.

  29. Giles F, le Coutre PD, Bhalla KN, et al.: Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase who failed prior imatinib and dasatinib therapy; updated results of a phase 2 study [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3234.

  30. Jabbour E, Kantarjian H, Baccarani M, et al.: Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase or accelerated phase [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3215.

  31. Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154–2160.

    Article  CAS  PubMed  Google Scholar 

  32. Kantarjian H, Talpaz M, O’Brien S, et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873–2878.

    Article  CAS  PubMed  Google Scholar 

  33. Hughes TP, Branford S, White DL, et al.: Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008, 112:3965–3973.

    Article  CAS  PubMed  Google Scholar 

  34. Castagnetti F, Palandri F, Amabile M, et al.: Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 2009, 113:3428–3434.

    Article  CAS  PubMed  Google Scholar 

  35. Baccarani M, Rosti G, Castagnetti F, et al.: Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497–4504.

    Article  CAS  PubMed  Google Scholar 

  36. Cortes J, Baccarani M, Guilhot F, et al.: Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: Tyrosine Kinase Inhibitor Optimization and Selectivity study. J Clin Oncol 2010, 28:424–430.

    Article  CAS  PubMed  Google Scholar 

  37. Baccarani M, Druker BJ, Cortes-Franco J, et al.: 24 months update of the TOPS study: a phase III, randomized, open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 337.

  38. Palandri F, Castagnetti F, Iacobucci I, et al.: The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010 (Epub ahead of print).

  39. •• Guilhot F, Preudhomme C, Guilhot J, et al.: Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib for the treatment of newly diagnosed chronic phase chronic myeloid leukaemia patients; confirmatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 340. This randomized study showed that the addition of IFN to imatinib led to an improved molecular response.

  40. Hehlmann R, Jung-Munkwitz S, Lauseker M, et al.: Randomized comparison of imatinib 800 mg vs. imatinib 400 mg +/− IFN in newly diagnosed BCR/ABL positive chronic phase CML: Analysis of molecular remission at 12 months; the German CML-Study IV. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 339.

  41. Simonsson B, Gedde-Dahl T, Markevärn B, et al.: A randomized phase II study comparing imatinib and the combination of imatinib and pegylated interferon alpha-2b in newly diagnosed non-high risk chronic myeloid leukemia (CML) patient in complete hematological remission after imatinib induction therapy [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 3280.

  42. Quintas-Cardama A, Kantarjian HM, Ravandi F, et al.: Immune modulation of minimal residual disease in patients with chronic myelogenous leukemia in early chronic phase: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated-interferon and GM-CSF. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2207.

  43. Cortes J, Jones D, O’Brien S, et al.: Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010, 28:398–404.

    Article  CAS  PubMed  Google Scholar 

  44. Bradeen HA, Eide CA, O’Hare T, et al.: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea(ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 2006, 108:2332–2338.

    Article  CAS  PubMed  Google Scholar 

  45. Cortes J, Jones D, O’Brien S, et al.: Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010, 28:392–397.

    Article  CAS  PubMed  Google Scholar 

  46. Quintas-Cardama A, Kantarjian H, Jones D, et al.: Delayed achievement of molecular responses is associated with increased risk of progression among patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with imatinib (IM). Blood 2006, 108:Abstract 432.

  47. Martinelli G, Castagnetti F, Poerio A, et al.: Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML WP [abstract]. J Clin Oncol 2009, 27(Suppl):Abstract 7074.

  48. •• Saglio G, Kim DW, Issaragrisil S, et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010 June 5 (Epub ahead of print). This phase 3, randomized study showed the superiority of nilotinib as first-line therapy for patients with newly diagnosed CML, as compared to imatinib.

  49. •• Kantarjian H, Shah NP, Hochhaus A, et al.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010 June 5 (Epub ahead of print). This phase 3, randomized study showed the superiority of dasatinib as first-line therapy for patients with newly diagnosed CML, as compared to imatinib.

  50. Verma D, Kantarjian H, Shan J, et al.: Sustained complete molecular response to imatinib in chronic myeloid leukemia (CML): a target worth aiming and achieving [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 505.

  51. Rousselto P, Huguet F, Rea D, et al.: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58–60.

    Article  Google Scholar 

  52. Mahon FX, Rea D, Guilhot F, et al.: Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 859.

  53. Cortes J, O’Brien S, Kantarjian H, et al.: Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004, 104:2204–2205.

    Article  CAS  PubMed  Google Scholar 

  54. Bonifazi F, de Vivo A, Rosti G, et al.: Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 2001, 98:3074–3081.

    Article  CAS  PubMed  Google Scholar 

  55. Burchert A, Neubauer A: Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 2005, 46:167–175.

    Article  CAS  PubMed  Google Scholar 

  56. • Burchert A, Müller M, Kostrewa P, et al.: Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010, 28:1429–1435. This study suggests the possible role that IFN may play as maintenance therapy.

    Article  CAS  PubMed  Google Scholar 

  57. Mohty M, Yong AS, Szydlo RM, et al.: The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007, 110:380–383.

    Article  CAS  PubMed  Google Scholar 

  58. Bocchia M, Gentili S, Abruzzese E, et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365:657–662.

    CAS  PubMed  Google Scholar 

  59. Bocchia M, Defina M, Ippoliti M, et al.: BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 648.

  60. Smith BD, Kasamon YL, Kowalski J, et al.: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010, 16:338–347.

    Article  CAS  PubMed  Google Scholar 

  61. Puttini M, Coluccia AM, Boschelli F, et al.: In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006, 66:11314–11322.

    Article  CAS  PubMed  Google Scholar 

  62. Cortes J, Kantarjian HM, Brümmendorf T, et al.: Safety and efficacy of bosutinib (SKI-606) in patients with chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib. J Clin Oncol (American Society of Clinical Oncology) 2010, 28(7 Suppl):abstract 6502.

    Google Scholar 

  63. Cortes J, Paquette R, Talpaz M, et al.: Preliminary clinical activity in a phase I trial of the bcr-abl/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3232.

  64. Paquette RL, Shah NP, Sawyers CL, et al.: PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 1030.

  65. Cortes J, Dombret H, Schafhausen P, et al.: Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 864.

  66. Rivera VM, Xu Q, Wang F, et al.: Potent antitumor activity of AP24534, an orally active inhibitor of Bcr-Abl variants including T315I, in in vitro and in vivo models of chronic myeloid leukemia (CML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 1032.

  67. Cortes J, Talpaz M, Deininger M, et al.: A phase I trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 643.

  68. Squires MS, Reule M, Curry J, et al.: AT9283, a potent inhibitor of BCR-ABL T315I, is active in CML models [abstract 2820]. Presented at the Annual Meeting of the American Association of Cancer Research. San Diego, CA; April 12–16, 2008.

  69. Van Etten RA, Chan WW, Zaleskas VM, et al.: DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 142.

  70. Cortes J, Khoury HJ, Nicolini FE, et al.: Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients who harbor the Bcr-Abl T315I mutation—results of an ongoing multicenter phase 2/3 study. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 644.

Download references

Disclosure

Drs. Cortes and Kantarjian both have research support from Novartis, BMS, and Pfizer.

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX, 77030, USA

    Meetu Agrawal, Ravin J. Garg, Hagop Kantarjian & Jorge Cortes

Authors
  1. Meetu Agrawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravin J. Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hagop Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jorge Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge Cortes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agrawal, M., Garg, R.J., Kantarjian, H. et al. Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?. Curr Oncol Rep 12, 302–313 (2010). https://doi.org/10.1007/s11912-010-0116-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-010-0116-1

Keywords

Search

Navigation